Portal de Periódicos da CAPES

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial

2021; Elsevier BV; Volume: 9; Issue: 5 Linguagem: Inglês

10.1016/s2213-2600(21)00081-3

2213-2619

Arvinder S. Soin, K Kavin Kumar, Narendra S. Choudhary, Pooja Sharma, Yatin Mehta, Sushila Kataria, Deepak Govil, Vikas Deswal, Dhruva Chaudhry, Pawan Singh, Ashish Gupta, Vikas Agarwal, Suresh Kumar, Shashikala Sangle, Rajesh Chawla, Suneetha Narreddy, Rahul Pandit, Vipul Kumar Mishra, Manoj Goel, Athimalaipet V Ramanan,

SARS-CoV-2 and COVID-19 Research

Global randomised controlled trials of the anti-IL-6 receptor antibody tocilizumab in patients admitted to hospital with COVID-19 have shown conflicting results but potential decreases in time to discharge and burden on intensive care. Tocilizumab reduced progression to mechanical ventilation and death in a trial population enriched for racial and ethnic minorities. We aimed to investigate whether tocilizumab treatment could prevent COVID-19 progression in the first multicentre randomised controlled trial of tocilizumab done entirely in a lower-middle-income country.